Early Promise for PCSK9 Inhibition in Severe COVID-19

(MedPageToday) PCSK9 inhibitors may have a role in dampening vascular inflammation to improve outcomes in severe COVID-19, a pilot study suggested. Among people with severe COVID-19 with respiratory failure and heightened inflammation, the advantage of getting PCSK9 inhibition therapy was a significantly reduced incidence of death or need for intubation at 30 days (23.3% vs 53.3% with placebo), according to Eliano Navarese, MD, PhD, of Nicolaus Copernicus University in Bydgoszcz, Poland, and colleagues on the IMPACT-SIRIO 5 team.